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Abstract
Objective—To investigate the effects of daily chromium picolinate supplementation on serum
measures of glucose tolerance and insulin sensitivity in patients at high risk for type 2 diabetes
mellitus.
Methods—We conducted a randomized, double-blind, placebo-controlled, modified cross-over
clinical trial with 6-month sequences of intervention and placebo followed by a 6-month
postintervention assessment. Adult patients with impaired fasting glucose, impaired glucose
tolerance, or metabolic syndrome were enrolled. Participants received 6-month sequences of
chromium picolinate or placebo at 1 of 2 dosages (500 or 1000 mcg daily). Primary outcome
measures were change in fasting plasma glucose, 2-hour plasma glucose during oral glucose
tolerance testing, fasting and 2-hour insulin, and homeostasis model assessment of insulin
resistance (HOMA-IR). Secondary outcomes included anthropometric measures, blood pressure,
endothelial function, hemoglobin A1c, lipids, and urinary microalbumin.
Results—Fifty-nine participants were enrolled. No changes were seen in glucose level, insulin
level, or HOMA-IR (all, P>.05) after 6 months of chromium at either dosage level (500 mcg or
1000 mcg daily) when compared with placebo. None of the secondary outcomes improved with
either chromium dosage compared with placebo (P>.05).
Conclusions—Chromium supplementation does not appear to ameliorate insulin resistance or
impaired glucose metabolism in patients at risk for type 2 diabetes and thus is unlikely to attenuate
diabetes risk.
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Impaired glucose tolerance (IGT), impaired fasting glucose (IFG), and metabolic syndrome
are considered precursors to type 2 diabetes mellitus (1). Endothelial dysfunction is also
associated with increased risk for diabetes and is directly linked to insulin resistance (2) and
hyperglycemia.
Although pharmacotherapy with such drugs as metformin, acarbose, orlistat, and
thiazolidinediones can reduce risk of type 2 diabetes (3), their cost and potential adverse
effects can be objectionable to patients who do not yet have an actual disease (4). Intensive
diet and lifestyle change can have an important role in diabetes prevention (5), although
adherence to these regimens is often difficult (6).
The micronutrient chromium is of interest in this regard as a potential means of improving
glucose tolerance (7,8) by reducing insulin resistance (9). Chromium picolinate is widely
marketed to the public with diverse health claims pertaining to glucose metabolism, insulin
action, muscle mass, weight control, and diabetes prevention (10). In 2002, estimated sales
of chromium-based supplements was $85 million (11). Indeed, one of the more common
nutrition-related questions posed by patients with or at risk for diabetes to practicing
endocrinologists concerns the effectiveness of chromium.
To assess the efficacy of this popular nutritional supplement, we performed a randomized
controlled trial designed to investigate the effects of daily chromium picolinate
supplementation for 6 months at 2 dosage levels on serum measures of glucose tolerance
and insulin sensitivity. Because of the association of derangements in these metabolic
abnormalities with endothelial dysfunction, brachial artery reactivity was also assessed
before and after therapy.
RESEARCH DESIGN AND METHODS
Participants
Patients enrolled were 18 years or older and were identified as having IGT, IFG, or
metabolic syndrome.
IGT was diagnosed by American Diabetes Association guidelines (1), which require the
following 2 criteria: (a) a plasma glucose concentration 2 hours after consuming 75 g of
glucose of at least 140 mg/dL, but below 200 mg/dL, and (b) a fasting plasma glucose (FPG)
concentration less than 126 mg/dL.
IFG was diagnosed using the American Diabetes Association criteria of a FPG concentration
of 100 mg/dL or greater, but less than 126 mg/dL (1).
Metabolic syndrome was diagnosed using National Cholesterol Education Panel Adult
Treatment Panel III criteria (12), requiring the presence of 3 of the following 5 criteria:
waist circumference greater than 102 cm in men or greater than 88 cm in women;
triglyceride concentration 150 mg/dL or higher; high-density lipoprotein cholesterol
concentration less than 40 mg/dL in men or less than 50 mg/dL in women; blood pressure
greater than 130/greater than 85 mm Hg; and FPG concentration 100 mg/dL or higher.
Patients were excluded if they were diabetic (FPG concentration greater than 126 mg/dL; 2-
hour plasma glucose concentration greater than 200 mg/dL). Other exclusion criteria
included self-reported hospitalization for treatment of cardiovascular disease 6 months
before enrollment, serum creatinine concentration greater than 2.0 mg/dL at baseline, self-
reported pancreatitis, recent or significant abdominal surgery, pregnancy and/or intention to
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become pregnant during the study, polycystic ovarian syndrome or irregular menses, or use
of chromium supplements less than 1 month before screening.
Patients were excluded if they were taking drugs thought to affect glucose metabolism and/
or endothelial function (glucocorticoids, antineoplastic agents, psychoactive agents, and
bronchodilators). Patients taking antihypertensive drugs and lipid-lowering agents were
allowed to participate provided that dosages were stable for 3 months before enrollment.
Ethical and Safety Considerations
The study protocol and consent form were approved by the Griffin Hospital (Derby,
Connecticut) Institutional Review Board and the Yale University (New Haven, Connecticut)
Human Investigation Committee and the study was conducted in accordance with the
Declaration of Helsinki. Written informed consent was obtained, and all participants
received a total of $475 (divided among assessment visits) as compensation for their
participation. For safety monitoring, unblinded subject treatment assignment was maintained
by a data and safety monitoring board.
Study Design and Interventions
This study was a randomized, double-blind, placebo controlled, modified cross-over clinical
trial to investigate the effects of daily chromium supplementation for 6 months at 2 dosage
levels (500 mcg and 1000 mcg of chromium picolinate daily) on serum measures of insulin
sensitivity and glucose tolerance in adults with IGT, IFG, and metabolic syndrome.
The study used a modified cross-over (Latin square) design encompassing both paired
(cross-over) and unpaired comparisons with statistical methods and sample size tailored to
serve both purposes (see Statistical Analysis).
The study was designed and powered to compare the 6-month effects of 500 mcg to 1000
mcg of chromium on insulin resistance (homeostasis model assessment of insulin resistance
[HOMA-IR]), which provided adequate power (see Statistical Analysis) to detect a change
in 2-hour plasma glucose and endothelial function. Effects of chromium at each dosage were
compared with placebo as a paired (cross-over) comparison after 6 months of use. Because
the time required for chromium to wash out fully is unknown, a posttreatment phase of 6
months was incorporated into the design following 12 months of intervention and placebo
(Fig. 1).
Patients meeting eligibility criteria were randomly assigned to 500 mcg daily or 1000 mcg
daily of chromium picolinate and then further randomized to chromium/placebo or placebo/
chromium sequences. After completing the initial 6-month period, participants immediately
crossed over to the alternate assignment (Fig. 1). All investigators and participants were
blinded to treatment assignment.
The 2 dosages of chromium picolinate (500 mcg or 1000 mcg daily) and placebo capsules
came in the form of capsules similar in shape, size, and appearance, donated by Nutrition 21,
Inc (Purchase, New York). Placebo capsules were indistinguishable from those containing
chromium. Supplying pharmacy personnel encoded the treatment supplements and matching
placebos.
Outcome Measures
The primary outcome measures were serum insulin, HOMA-IR, 2-hour plasma glucose,
fasting plasma glucose, and 2-hour insulin during oral glucose tolerance testing assessed
after 6 months of chromium use. Insulin resistance was calculated with the HOMA-IR by
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using the following equation: HOMA-IR = fasting plasma insulin (µIU/mL) × FPG (mmol/
L) × 22.5 (13).
Secondary outcome measures included weight, waist circumference, body mass index
(BMI), blood pressure, endothelial function as assessed by flow-mediated dilatation (FMD)
of the brachial artery, blood glycohemoglobin, total serum cholesterol, serum high-density
lipoprotein cholesterol, serum low-density lipoprotein cholesterol, serum triglycerides, and
urinary microalbumin-to-creatinine ratio.
Participants were weighed after removing their heavy outer garments and shoes, standing on
a calibrated scale, standing in the center of the platform with weight distributed evenly to
both feet. Waist circumference was measured at the level of the umbilicus in a horizontal
position. BMI was calculated at each visit. Blood pressure was determined using the
Datascope Accutorr Plus automatic digital blood pressure device with the participant supine.
Our endothelial function assessment methods have been previously reported (14). In brief,
endothelial function as FMD was measured noninvasively in the right brachial artery with
high-frequency ultrasonography (Sonos 4500; Phillips Medical Systems, Andover,
Massachusetts) in accordance with published guidelines (15). Measures of vessel diameter
and flow velocity were obtained by a single dedicated vascular clinical research specialist
blinded to subject treatment status. To account for potential variability in stimulus strength,
FMD was divided by flow at 15 seconds after cuff deflation to create a stimulus-adjusted
response measure. Endothelial function was assessed in the fasting state, with a nitroglycerin
control, and at 90 minutes post-OGTT to assess the change in FMD between fasting and fed
states. (A glucose load has been associated with transient endothelial dysfunction in healthy,
prediabetic, and diabetic populations [16–19]; nutritional interventions [14,20,21] have been
shown to mitigate acute [immediate] endothelial dysfunction.)
Laboratory measures including FPG, 2-hour plasma glucose, glycohemoglobin, lipid panel,
and urinary markers were collected and analyzed at Griffin Hospital (Derby, Connecticut)
using standard procedures at each visit. Insulin concentrations were measured at the Yale
Center for Clinical Investigation Core Laboratory (New Haven, Connecticut).
Statistical Analysis
A sample size of 60 participants, allowing for 20% attrition and nonadherence, was
predicted to provide 90% power (8) to detect a minimal difference of 9.5% in HOMA
sensitivity between the 500-mcg and 1000-mcg arms (α = 0.05). A standard deviation of
10.1 was used on the basis of previous literature (22). This sample size also provided greater
than 80% power to detect a change of 15% in 2-hour plasma glucose concentration and
0.5% in FMD between the 500-mcg and 1000-mcg groups at 6 months.
Analysis was by intention-to-treat; 6-month postintervention analysis was conducted on
those having completed 6-month assessments (primary end point) in the cross-over design.
Missing individual data were addressed by the last observation carried forward method.
Statistical analysis was conducted using SAS software (Version 9.1, SAS Institute, Cary,
North Carolina). Independent samples t tests, chi-square tests, and Mann-Whitney tests were
used to compare participants at baseline. Descriptive and exploratory analyses of all
measured outcomes were performed before embarking on modeling or hypothesis testing
procedures. Normally distributed data were analyzed using repeated measures analysis of
variance to assess differences in intraindividual responses across treatments for all outcome
measures, while non-normally distributed data were analyzed using the Mann-Whitney test.
Assessment of treatment effects between dosage groups, where baseline between-group
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differences were observed to be either statistically significant (P<.05) or approaching trend-
level significance (P<.10), was conducted using analysis of covariance, with baseline values
entered into the model to control for those differences. The combined effect of independent
variables (age, sex, BMI at baseline, metabolic syndrome, and treatment sequence) and
treatment assignment on all outcome measures was assessed with multivariable models.
To assess the effect of different treatment assignments on outcome measures, we computed
95% confidence intervals (CI) for mean changes from baseline following each treatment
assignment. Comparisons across treatment assignments were made using the 95% CI around
the mean change of outcome measures from their baseline values. When the 95% CI of
mean change of one treatment assignment was not included within the 95% CI of mean
change of another treatment assignment (ie, nonoverlap), we considered the 2 treatment
assignments significantly different at P<.05. Mean change from baseline values of outcome
measures after each treatment assignment was considered significant when the 95% CI
around the mean change did not include zero.
RESULTS
Of the 243 persons screened for eligibility, 80 did not meet eligibility criteria, 47 refused to
participate, and 56 were not randomized for other reasons (Fig. 1). Sixty participants were
ultimately randomly assigned to 500-mcg (n = 30) or 1000-mcg (n = 30) sequences. One
participant in the 1000-mcg sequence withdrew consent after randomization because of time
commitment. Of the 59 participants enrolled, 56 completed 6-month assessments (primary
end point) and 50 participants completed the 6-month postintervention assessment (Fig. 1).
Spot checks of pill counts were done to assess regimen adherence; 92% of our sample
consumed more than 80% of assigned capsules.
Participants ranged in age from 31 to 88 years; the mean (± standard deviation) age of the
participants was 56.9 (±12.1) years; and 38 (64%) were women. Additional demographic
data are provided in Table 1. At baseline, 18 participants (64%) in the 500-mcg arm and 20
participants (74%) in the 1000-mcg arm were insulin resistant by HOMA-IR (>3.0) (13) (P
= .43). Furthermore, 14 participants (47%) in the 500-mcg arm and 19 participants (66%) in
the 1000-mcg arm had metabolic syndrome by National Cholesterol Education Panel Adult
Treatment Panel III criteria (12) (P = .19).
Primary Outcomes
No changes were observed in FPG, 2-hour plasma glucose levels, fasting or 2-hour post–oral
glucose tolerance test insulin levels, or HOMA-IR as compared with placebo after 6 months
of chromium use in either the 500-mcg and 1000-mcg arms (Table 2).
Secondary Outcomes
Six months of chromium supplementation (500 mcg or 1000 mcg) was not associated with
any significant changes in glycohemoglobin, weight, waist circumference, BMI, blood
pressure, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein
cholesterol, triglycerides, or urine microalbumin compared with placebo. A modest change
in endothelial function at 6 months was noted in comparing the 500-mcg arm with the 1000-
mcg arm; endothelial function improved in the former group (+0.9% [−0.5 to 2.4] vs −1.6%
[−3.0 to −0.2] in the latter group at 2-hour post–oral glucose tolerance test) and is of
uncertain significance, given the lack of other changes in this parameter across groups
(Table 2) and the inverse dose-response. There were no other significant changes observed
at the 6-month postintervention assessment on all remaining outcome measures (Table 3).
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No significant changes were observed in any of the primary or secondary outcome measures
after controlling for age, sex, BMI at baseline, metabolic syndrome, treatment sequence, and
treatment assignment.
Four participants developed type 2 diabetes during the course of the study (FPG >126 mg/
dL or 2-hour plasma glucose >200 mg/dL). All 4 diabetic participants were in the 500-mcg
arm, although at the time of diagnosis, 2 were in the placebo-first sequence while 2 were in
the chromium-first sequence. No serious adverse events were reported.
DISCUSSION
In this randomized prospective study involving adult patients at risk for diabetes, chromium
supplementation, at 2 dosing levels, had no substantive effect on any direct measure of
glucose metabolism or indirect measures of insulin action. Chromium therefore appears to
be ineffective on markers thought to be related to the development of type 2 diabetes in
these high-risk patients. No differences were seen after 6 months of active treatment vs
placebo or after 6-month postintervention assessment. The single significant improvement in
endothelial function between participants in the 500-mcg arm compared with participants in
the 1000-mcg arm is probably a statistical artifact or random finding due to multiple
comparisons, inconsistency with a dose-response effect, and lack of corroboration seen in
the stimulus-adjusted response measure. In previous work, including our own (14,20,23,24),
we detected a significant improvement in endothelial function (as FMD) with a “cardiac risk
modification” strategy (25). One proposed explanation is that endothelial function may
aggregate the effect of numerous biomarkers of circulatory health. Accordingly, the impact
of a single intervention may be amplified when endothelial function is measured. Thus, a
positive effect of chromium on endothelial function might have suggested a benefit too
subtle to capture with our relatively more crude metabolic measures. However, the absence
of any such effect buttresses our conclusion that chromium was without substantial benefit
in this population.
Our results are congruent with findings from a recent study performed in our laboratory
showing no effect of 1000 mcg of chromium picolinate on weight loss and adiposity in 80
overweight individuals (26). Other recent trials have found similar results. In a randomized
trial of 63 persons with metabolic syndrome, Iqbal et al found no effect of 1000 mcg of
chromium picolinate on insulin sensitivity, glucose metabolism, body weight, serum lipids,
or measures of inflammation and oxidative stress (27). Gunton et al found no changes in 1-
and 2-hour glucose tolerance, FPG, fasting insulin, HOMA-IR, and lipid measures in a 3-
month randomized controlled trial using 800 mcg of chromium in 40 patients with IGT (28).
Earlier studies had shown positive effects of chromium, but these involved smaller numbers
of subjects (7) and shorter treatment durations (8). Other previous studies suggested that the
primary factor for a clinical response to chromium supplementation is insulin resistance
(29–31). In subjects with type 2 diabetes using sulfonylurea agents, Martin et al (30)
demonstrated that chromium picolinate improves insulin sensitivity, improves glucose
control, and attenuates body weight and visceral fat compared with placebo. The
discrepancy between our results and those of Martin et al may possibly be explained by
differences in the study populations, with ours not including patients with diabetes, or by the
differential measures of insulin sensitivity used in the 2 studies. HOMA-IR is predominately
affected by hepatic sensitivity, while the hyperinsulinemic euglycemic clamp technique used
by Martin et al predominately assesses peripheral insulin sensitivity. Wang et al found that
baseline insulin sensitivity, as measured by clamp, accounted for nearly 40% of the variance
in the clinical response to chromium (31). Patients who were insulin resistant responded to
chromium supplementation to a greater degree than those who were not insulin resistant
(31).
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Strengths of our study include use of 2 doses commonly prescribed in clinical practice and
multiple outcome measures. Our study also incorporated a rigorous crossover design where
participants served as their own control, reducing variability in the results. A major
limitation of the study is a lack of a biomarker assessing serum chromium levels at baseline
and during therapy. Although current evidence suggests that chromium deficiency in
humans are rare, it is possible that chromium-deficient populations may respond to
chromium supplementation. Other limitations include relatively broad inclusion criteria. IFG
and IGT, especially when those abnormalities are found in isolation (ie, IFG alone or IGT
alone), may represent different pathophysiologic derangements and differential risks for
developing future diabetes (32). Although participants in our study were largely insulin
resistant with a baseline mean HOMA-IR of 4.2, it is conceivable that a greater degree of
insulin resistance may be required to detect a robust response to chromium. It is also
possible that HOMA-IR, which as mentioned, is largely influenced by hepatic insulin
sensitivity (32), is not refined enough as a marker to exhibit an insulin-sensitizing effect of
chromium. Despite these concerns, if chromium had any beneficial response on glucose
metabolism in participants in our study, improvement in some of the parameters we
measured would be expected. We note, for example, that our postchallenge insulin levels
(post–oral glucose tolerance testing), which reflect both hepatic and peripheral insulin
sensitivity (33), were unchanged compared with those of the placebo group.
CONCLUSION
Chromium supplementation does not appear to ameliorate insulin resistance or impaired
glucose metabolism, and thus is unlikely to attenuate diabetes risk. Endocrinologists should
therefore not endorse this therapy as part of a diabetes prevention strategy.
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Table 1
Baseline Characteristics of Patients in the 500-mcg and 1000-mcg Armsa
Variable
Groups A and B
500 mcg
(n = 30)
Groups C and D
1000 mcg
(n = 29) P value
Sex, No. (%)
    Male 11 (37) 10 (34) >.99
Age, y 54.7 (10.6) 59.3 (13.3) .15
Anthropometric Measures
    Weight, lb 90.5 (13.8) 91.4 (22.9) .84
    Waist circumference, cm 107.2 (7.9) 110.4 (15.8) .41
    Body mass index, kg/m2 33.4 (6.1) 32.7 (5.6) .64
Metabolic syndromeb
    Yes, No. (%) 14 (46.7) 19 (65.5) .19
Blood pressure
    Systolic, mm Hg 129.3 (12.3) 129.6 (14.4) .93
    Diastolic, mm Hg 75.6 (10.7) 73.4 (12.5) .79
Laboratory values
    Fasting plasma insulin, µIU/mL 15.6 (8.1) 18.2 (11.6) .33
    2-Hour OGTT insulin, µIU/mLc 61.0 (18, 226) 77.5 (14, 483) .32
    Fasting plasma glucose, mg/dL 103.8 (10.8) 98.9 (9.0) .06
    2-hour OGTT glucose, mg/dL 131.8 (41.9) 125.8 (30.0) .53
    HOMA-IRd 4.0 (2.0) 4.4 (2.7) .54
    Whole blood hemoglobin A1c, % 5.7 (0.4) 5.7 (0.5) .90
    Serum total cholesterol, mg/dL 187.8 (26.5) 185.0 (36.4) .73
    Serum HDL cholesterol, mg/dL 51.7 (11.6) 45.0 (11.6) .03
    Serum LDL cholesterol, mg/dL 112.0 (26.5) 116.2 (29.2) .56
    Serum triglycerides, mg/dL 120.1 (49.3) 120.5 (48.2) .98
    Urine microalbuminc 5.6 (0.0, 90.1) 7.1 (0.0, 57.8) .24
    Serum creatinine, mg/dL 0.9 (0.2) 0.9 (0.2) .53
Endothelial function
    FMD pre OGTT, % Δ 7.8 (3.9) 9.5 (4.7) .15
    FMD pre OGTT nitro, % Δ 15.3 (5.7) 16.2 (5.9) .56
    FMD post OGTT, % Δ 9.5 (4.5) 10.2 (5.0) .56
    SARM pre OGTT 0.1 (0.1) 0.1 (0.1) .50
    SARM post OGTT 0.1 (0.1) 0.1 (0.1) .42
Abbreviations: FMD, flow-mediated dilatation; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance;
LDL, low-density lipoprotein; OGTT, oral glucose tolerance test; SARM, stimulus-adjusted response measure.
a
Data are expressed as mean (standard deviation) unless otherwise noted.
b
Metabolic syndrome as defined by National Cholesterol Education Program Adult Treatment Panel III criteria.
c
Values for 2-hour OCTT and microalbumin are expressed as median (minimum, maximum).
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d
HOMA-IR by using the mathematical approximation: HOMA-IR = fasting plasma insulin (µIU/mL) × fasting plasma glucose (mmol/L) × 22.5.
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Table 2
Changes From Baseline Values in 500-mcg and 1000-mcg Arms After 6 Monthsa
Group A and B Group C and D
Variable 500 mcg (n = 30) Placebo (n = 30) 1000 mcg (n = 29) Placebo (n = 29)
Anthropometric measures
    Weight, lb −0.1 (−3.1 to 2.8) −1.4 (−4.3 to 1.6) 2.6 (−0.5 to 5.7) 0.4 (−2.7 to 3.5)
    Waist circumference, cm −0.1 (−2.1 to 1.9) 0.9 (−1.1 to 2.9) 0.1 (−2.7 to 2.8) 1.6 (−1.2 to 4.3)
    Body mass index, kg/m² −0.1 (−0.6 to 0.5) −0.3 (−0.8 to 0.2) 0.4 (−0.1 to 0.9) −0.0 (−0.6 to 0.5)
Blood pressure
    Systolic, mm Hg 1.3 (−3.3 to 5.8) −1.2 (−5.7 to 3.3) 1.3 (−3.2 to 5.7) 4.6 (0.2 to 9.0)
    Diastolic, mm Hg 2.8 (−0.6 to 6.1) 3.4 (−0.1 to 6.8) 0.1 (−3.0 to 3.3) 1.6 (−1.6 to 4.7)
Laboratory values
    Fasting plasma insulin, µIU/mL 1.3 (−1.0 to 3.5) −1.0 (−3.2 to 1.2) 0.7 (−1.6 to 3.0) −0.4 (−2.7 to 1.9)
    2-Hour OGTT insulin, µIU/mL −1.0 (−11.6 to 9.6) −7.4 (−18.0 to 3.1) 6.3 (−28.5 to 41.2) 5.1 (−29.7 to 39.9)
    Fasting plasma glucose, mg/dL −1.0 (−3.9 to 1.9) −2.8 (−5.7 to 0.1) −0.3 (−3.8 to 3.1) −0.5 (−3.9 to 3.0)
    2-hour OGTT glucose, mg/dL 0.8 (−13.2 to 14.1) −0.1 (−14.1 to 13.9) −2.9 (−15.0 to 9.2) 5.7 (−6.4 to 17.8)
    HOMA-IRb 0.3 (−0.4 to 1.1) −0.4 (−1.1 to 0.4) 0.2 (−0.4 to 0.8) −0.1 (−0.7 to 0.5)
    HOMA-IRb, % Δ 7.1 (−6.7 to 21.0) −6.9 (−20.8 to 6.9) 5.8 (−8.8 to 20.2) 7.1 (−7.5 to 21.6)
    Whole blood hemoglobin A1c, % 0.1 (0.0 to 0.2) 0.1 (0.0 to 0.2) 0.0 (−0.1 to 0.1) 0.1 (−0.0 to 0.2)
    Serum total cholesterol, mg/dL −2.9 (−11.0 to 5.1) −6.8 (−14.9 to 1.2) −3.1 (−12.5 to 6.3) 2.4 (−7.0 to 11.8)
    Serum HDL cholesterol, mg/dL 1.9 (−0.1 to 4.0) 0.6 (−1.4 to 2.6) 3.1 (−2.6 to 8.9) 0.3 (−5.4 to 6.0)
    Serum LDL cholesterol, mg/dL −6.4 (−13.2 to 0.4) −7.1 (−13.9 to −0.3) −5.9 (−14.6 to 2.8) 0.03 (−8.7 to 8.8)
    Serum triglycerides, mg/dL 8.7 (−7.5 to 24.9) −0.9 (−17.1 to 15.4) −2.9 (−17.1 to 11.2) 10.4 (−3.8 to 24.5)
    Urine microalbumin −1.4 (−3.9 to 1.2) −2.5 (−5.1 to 0.1) 1.2 (−2.8 to 5.2) 1.6 (−2.4 to 5.6)
    Serum creatinine, mg/dL 0.1 (−0.0 to 0.0) 0.0 (−0.0 to 0.0) 0.0 (−0.0 to 0.0) 0.0 (−0.0 to −0.0)
Endothelial function
    FMD pre OGTT, % Δ 1.0 (−0.2 to 2.3) 1.0 (−0.3 to 2.7) −0.1 (−1.1 to 1.4) −0.2 (−1.1 to 1.5)
    FMD pre OGTT nitro, % Δ 1.2 (−1.0 to 3.5) 0.1 (−2.1 to 2.4) 0.1 (−1.8 to 1.9) −0.7 (−1.1 to 2.6)
    FMD post OGTT, % Δ 0.9 (−0.5 to 2.4) 0.1 (−1.3 to 1.6) −1.6 (−3.0 to −0.2) −0.4 (−1.8 to 1.0)
    SARM Pre OGTT 0.0 (−0.0 to 0.0) 0.0 (−0.0 to 0.0) 0.0 (−0.0 to 0.0) 0.0 (−0.0 to 0.0)
    SARM Post OGTT −0.0 (−0.1 to 0.1) 0.0 (−0.0 to 0.1) 0.0 (−0.0 to 0.0) 0.0 (−0.0 to 0.0)
Abbreviations: FMD, flow-mediated dilatation; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance;
LDL, low-density lipoprotein; OGTT, oral glucose tolerance test; SARM, stimulus-adjusted response measure.
a
Data are expressed as mean change (95% confidence interval).
b
HOMA-IR by using the mathematical approximation: HOMA-IR = fasting plasma insulin µIU/mL) × fasting plasma glucose (mmol/L) × 22.5.
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Table 3














    Weight, lb −1.1 (−7.7 to 1.8) −2.1 (−8.4 to 4.3) −2.7 (−7.2 to 1.8) −2.5 (−7.0 to 2.0)
    Body mass index, kg/m2 −0.2 (−1.4 to 1.0) −0.4 (−1.5 to 0.8) −0.4 (−1.1 to 0.3) −0.4 (−1.1 to 0.3)
Blood pressure
    Systolic, mm Hg −0.1 (−6.8 to 5.0) −1.7 (−7.4 to 3.9) −6.8 (−15.3 to 1.7) 3.8 (−4.7 to 12.3)
    Diastolic, mm Hg 4.6 (−0.2 to 9.4) 6.0 (1.6 to 10.4) −0.8 (6.9 to 5.3) 1.8 (−4.3 to 7.9)
Laboratory values
    Fasting plasma insulin, µIU/mL −4.2 (−8.1 to 0.3) −1.3 (−5.0 to 2.4) −0.2 (−5.4 to 5.0) −1.2 (−6.4 to 4.0)
    2-Hour OGTT insulin, µIU/mL −7.5 (−32.9 to 18.0) −10.6 (−36.1 to 14.8) −13.6 (−87.8 to 60.6) −0.5 (−74.7 to 73.6)
    Fasting plasma glucose, mg/dL −7.4 (−14.6 to 0.3) −3.8 (−10.0 to 2.4) −1.7 (−10.9 to 7.5) 0.3 (−8.9 to 9.5)
    2-hour OGTT glucose, mg/dL −18.0 (−39.3 to 3.3) −10.3 (−28.7 to 8.2) −2.7 (−26.5 to 21.10 −2.8 (−26.6 to 21.0)
    HOMA-IRc −1.5 (−2.9 to −0.0) −0.5 (−1.8 to 0.7) −0.2 (−1.7 to 1.3) −0.3 (−1.8 to 0.7)
    HOMA-IRc, % Δ −22.6 (−50.2 to 5.1) −8.6 (−32.2 to 14.9) 11.5 (−26.3 to 49.4) 5.3 (−32.6 to 43.2)
    Whole blood hemoglobin A1c, % 0.2 (−0.0 to 0.4) 0.1 (−0.1 to 0.3) 0.1 (−0.2 to 0.5) 0.3 (−0.0 to 0.6)
    Serum total cholesterol, mg/dL 13.1 (−7.5 to 33.7) −4.5 (−23.3 to 14.3) −8.8 (−23.7 to 6.1) −7.2 (−22.1 to 7.7)
    Serum HDL cholesterol, mg/dL 5.8 (−1.8 to 9.8) 1.7 (−2.0 to 5.3) 0.9 (−2.7 to 4.5) 2.3 (−1.2 to 5.9)
    Serum LDL cholesterol, mg/dL 3.1 (−14.0 to 20.2) −7.2 (−22.8 to 8.5) −11.9 (−27.4 to 3.6) −10.3 (−25.8 to 5.2)
    Serum triglycerides, mg/dL 22.7 (−18.0 to 63.4) 11.6 (−25.5 to 48.7) 9.1 (−6.2 to 24.4) 5.0 (−10.3 to 20.3)
    Urine microalbumin 3.1 (−7.4 to 13.5) −6.6 (−17.1 to 3.8) −3.5 (−10.6 to 3.5) 0.6 (−6.4 to 7.7)
    Serum creatinine, mg/dL −0.0 (−0.1 to 0.0) −0.0 (−0.1 to 0.0) −0.0 (−0.1 to 0.1) 0.1 (−0.0 to 0.2)
Endothelial function
    FMD pre OGTT, % Δ 1.9 (−0.6 to 4.3) 1.5 (−0.9 to 3.9) 1.6 (−0.7 to 3.8) 0.8 (−1.5 to 3.0)
    FMD pre OGTT nitro, % Δ 3.7 (−1.9 to 9.2) −0.0 (−5.1 to 5.0) −2.8 (−6.5 to 1.0) −0.2 (−3.7 to 3.4)
    FMD post OGTT, % Δ −0.4 (−3.8 to 2.9) 0.1 (−3.2 to 3.4) 0.5 (−2.5 to 3.6) −0.4 (−3.7 to 2.8)
    SARM pre OGTT −0.0 (−0.1 to 0.1) 0.0 (−0.1 to 0.1) 0.0 (−0.0 to 0.1) 0.0 (−0.0 to 0.1)
    SARM post OCTT −0.1 (−0.2 to 0.1) 0.1 (−0.1 to 0.2) 0.0 (−0.0 to 0.1) 0.0 (−0.0 to 0.1)
Abbreviations: FMD, flow-mediated dilatation; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance;
LDL, low-density lipoprotein; OGTT, oral glucose tolerance test; SARM, stimulus-adjusted response measure.
a
Data are expressed as mean change (95% confidence interval).
b
By design, the immediate cross-over of groups B and D from placebo to intervention did not allow for 6-month post-placebo data collection (see
Fig. 1).
c
HOMA-IR by using the mathematical approximation: HOMA-IR = fasting plasma insulin (µIU/mL) × fasting plasma glucose (mmol/L) × 22.5.
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